SOUTH SAN FRANCISCO - Denali Therapeutics Inc. (NASDAQ:DNLI) announced today that the U.S. Food and Drug Administration granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy for treating neurologic manifestations of Hunter syndrome in pediatric patients weighing at least 5 kg. The company's stock surged 4.5% following the announcement, trading near its 52-week high with shares up 56% over the past six months. With a market capitalization of $3.5 billion, Denali has seen its stock climb 27% year-to-date.
The approval marks the first new FDA-approved treatment option for Hunter syndrome in nearly 20 years. AVLAYAH is designed to cross the blood-brain barrier using Denali's TransportVehicle platform, which binds to the transferrin receptor to deliver the IDS enzyme to peripheral tissues and the central nervous system.
Hunter syndrome, also known as mucopolysaccharidosis type II, is a rare genetic disease affecting approximately 500 individuals in the United States. The condition results from a deficiency in the iduronate 2-sulfatase enzyme, causing glycosaminoglycans to accumulate in cells throughout the body, including the brain.
The approval is based on a 91% reduction in cerebrospinal fluid heparan sulfate levels from baseline by week 24 of treatment in a Phase 1/2 clinical trial. At week 24, 93% of AVLAYAH-treated patients had cerebrospinal fluid heparan sulfate levels within the range of individuals without Hunter syndrome, according to the press release statement. According to InvestingPro data, four analysts have revised their earnings upwards for the upcoming period, suggesting growing confidence in the company's commercial prospects. The platform also notes that Denali holds more cash than debt on its balance sheet, providing financial flexibility for the product launch.
The most common adverse reaction observed was infusion-related reactions. Continued approval may be contingent upon verification of clinical benefit in the ongoing Phase 2/3 COMPASS confirmatory trial.
AVLAYAH is administered once weekly and will be available in the U.S. shortly after approval. The FDA granted Denali a Rare Pediatric Disease Priority Review Voucher in connection with the approval.
The therapy is indicated for presymptomatic or symptomatic pediatric patients prior to advanced neurologic impairment and is not recommended for use in combination with other enzyme replacement therapies.
In other recent news, Denali Therapeutics has been the focus of several analyst evaluations and company developments. Jefferies reiterated a Buy rating with a $40 price target, highlighting the promising gene therapy outlook for Denali's Tivi/DNL310 treatment for Hunter syndrome, which has shown positive Phase I/II data. Meanwhile, Wolfe Research initiated coverage with a Peerperform rating, emphasizing Denali's TransportVehicle platform's enhanced brain exposure delivery capabilities. Denali is also set to present clinical data at the 22nd Annual WORLDSymposium, showcasing developments in its Enzyme Transport Vehicle programs for rare diseases like Hunter syndrome and Sanfilippo syndrome type A.
Goldman Sachs maintained its Buy rating and $35 price target, noting the potential launch of tividenofusp alfa for Hunter syndrome, supported by completed FDA meetings and ongoing labeling discussions. UBS also initiated a Buy rating with a $25 price target, expecting FDA approval for Denali's DNL310 for Hunter syndrome, which is under review with an April 5, 2026, PDUFA date. These recent developments reflect significant interest and optimism from analysts regarding Denali's therapeutic pipeline and regulatory progress.